Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Adenine
/ administration & dosage
Agammaglobulinaemia Tyrosine Kinase
/ antagonists & inhibitors
Aged
Aged, 80 and over
Bacterial Infections
/ chemically induced
Case-Control Studies
Enzyme Inhibitors
/ administration & dosage
Female
Humans
Invasive Fungal Infections
/ chemically induced
Italy
/ epidemiology
Lymphoproliferative Disorders
/ complications
Male
Middle Aged
Molecular Targeted Therapy
/ adverse effects
Opportunistic Infections
/ chemically induced
Piperidines
/ administration & dosage
Protein Kinase Inhibitors
/ administration & dosage
Purines
/ administration & dosage
Quinazolinones
/ administration & dosage
Retrospective Studies
Risk Factors
Virus Diseases
/ chemically induced
infections
lymphoproliferative diseases
targeted therapy
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
09
09
2020
received:
22
07
2020
accepted:
10
09
2020
pubmed:
16
10
2020
medline:
25
9
2021
entrez:
15
10
2020
Statut:
ppublish
Résumé
We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29·8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49·3% (75/152) and microbiologically defined infections (MDI) were 50·7% (77/152). Among 250 patients treated with ibrutinib, 28·8% (72/250) experienced one or more infections, for a total of 104 episodes. MDI were 49% (51/104). Bacterial infections were 66·7% (34/51), viral 19·6% (10/51) and invasive fungal diseases (IFD) 13·7% (7/51). Among the 112 patients treated with idelalisib, 32·1% (36/112) experienced one or more infections, for a total of 48 episodes. MDI were 54·2% (26/48). Bacterial infections were 34·6% (9/26), viral 61·5% (16/26) and IFD 3·8% (1/26). With ibrutinib, the rate of bacterial infections was significantly higher compared to idelalisib (66·7% vs. 34·6%; P = 0·007), while viral infections were most frequent in idelalisib (61·5% vs. 19·6%; P < 0·001). Although a higher rate of IFD was observed in patients treated with ibrutinib, the difference was not statistically significant (13·7% vs. 3·8% respectively; P = 0·18). Bacteria are the most frequent infections with ibrutinib, while viruses are most frequently involved with idelalisib.
Identifiants
pubmed: 33058237
doi: 10.1111/bjh.17145
pmc: PMC8246914
doi:
Substances chimiques
Enzyme Inhibitors
0
Piperidines
0
Protein Kinase Inhibitors
0
Purines
0
Quinazolinones
0
ibrutinib
1X70OSD4VX
Agammaglobulinaemia Tyrosine Kinase
EC 2.7.10.2
Adenine
JAC85A2161
idelalisib
YG57I8T5M0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
316-324Informations de copyright
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Leuk Lymphoma. 2015;56(10):2779-86
pubmed: 25726955
Blood. 2015 Nov 5;126(19):2213-9
pubmed: 26337493
Blood. 2015 Dec 17;126(25):2686-94
pubmed: 26472751
Lancet Oncol. 2017 Mar;18(3):297-311
pubmed: 28139405
Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):87-97.e5
pubmed: 31787589
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Blood. 2015 Apr 16;125(16):2497-506
pubmed: 25700432
Lancet Haematol. 2017 Mar;4(3):e114-e126
pubmed: 28257752
Blood Rev. 2018 Nov;32(6):499-507
pubmed: 29709246
Lancet Oncol. 2016 Feb;17(2):200-211
pubmed: 26655421
Leukemia. 2013 Jan;27(1):136-41
pubmed: 22781591
Leuk Lymphoma. 2018 Mar;59(3):625-632
pubmed: 28696801
J Clin Oncol. 2013 Jan 1;31(1):88-94
pubmed: 23045577
Lancet Oncol. 2014 Sep;15(10):1090-9
pubmed: 25150798
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S53-S70
pubmed: 29454849
J Clin Oncol. 2001 Aug 15;19(16):3611-21
pubmed: 11504743
Blood. 2018 Apr 26;131(17):1910-1919
pubmed: 29437592
Blood. 2018 Apr 26;131(17):1882-1884
pubmed: 29699994
Leuk Lymphoma. 2019 Jun;60(6):1572-1575
pubmed: 30632838
Leukemia. 2019 Oct;33(10):2527-2530
pubmed: 31086260
N Engl J Med. 2014 Jul 17;371(3):213-23
pubmed: 24881631
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Leuk Lymphoma. 2017 Dec;58(12):2981-2982
pubmed: 28554246
Lancet Haematol. 2017 Apr;4(4):e176-e182
pubmed: 28314699
Lancet Infect Dis. 2019 Aug;19(8):e260-e272
pubmed: 31153807
Br J Haematol. 2003 Aug;122(4):600-6
pubmed: 12899715
Blood. 2016 Oct 13;128(15):1940-1943
pubmed: 27503501
Clin Infect Dis. 2018 Aug 16;67(5):687-692
pubmed: 29509845
Blood. 2014 May 29;123(22):3390-7
pubmed: 24615777